Published in Methods Mol Med on January 01, 2003
A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci U S A (2004) 3.00
Increased abundance of opioid receptor heteromers after chronic morphine administration. Sci Signal (2010) 1.90
Hemopressin is an inverse agonist of CB1 cannabinoid receptors. Proc Natl Acad Sci U S A (2007) 1.70
Functional interactions between mu opioid and alpha 2A-adrenergic receptors. Mol Pharmacol (2003) 1.49
Identification of a μ-δ opioid receptor heteromer-biased agonist with antinociceptive activity. Proc Natl Acad Sci U S A (2013) 1.34
G protein-coupled receptor heteromerization: a role in allosteric modulation of ligand binding. Mol Pharmacol (2011) 1.27
Novel endogenous peptide agonists of cannabinoid receptors. FASEB J (2009) 1.25
β2-Adrenergic receptor signaling in the cardiac myocyte is modulated by interactions with CXCR4. J Cardiovasc Pharmacol (2010) 1.08
Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers. Biochem Pharmacol (2014) 1.05
Cannabinoid receptor 2-mediated attenuation of CXCR4-tropic HIV infection in primary CD4+ T cells. PLoS One (2012) 1.03
Opioid receptor heteromers in analgesia. Expert Rev Mol Med (2012) 0.94
Receptor heteromerization expands the repertoire of cannabinoid signaling in rodent neurons. PLoS One (2012) 0.91
Potentiation of μ-opioid receptor-mediated signaling by ketamine. J Neurochem (2011) 0.90
Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1/2-dependent mechanism. Neuropharmacology (2014) 0.88
GPR171 is a hypothalamic G protein-coupled receptor for BigLEN, a neuropeptide involved in feeding. Proc Natl Acad Sci U S A (2013) 0.87
Functional relevance of μ-δ opioid receptor heteromerization: a role in novel signaling and implications for the treatment of addiction disorders: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend (2011) 0.85
Opioid receptor function is regulated by post-endocytic peptide processing. J Biol Chem (2014) 0.85
Endothelin-converting enzyme 2 differentially regulates opioid receptor activity. Br J Pharmacol (2014) 0.81
Search for the "ideal analgesic" in pain treatment by engineering the mu-opioid receptor. IUBMB Life (2010) 0.80
Disease-specific heteromerization of G-protein-coupled receptors that target drugs of abuse. Prog Mol Biol Transl Sci (2013) 0.80
Mice deficient in endothelin-converting enzyme-2 exhibit abnormal responses to morphine and altered peptide levels in the spinal cord. J Neurochem (2011) 0.79
Identification of a small-molecule ligand that activates the neuropeptide receptor GPR171 and increases food intake. Sci Signal (2016) 0.78
Collybolide is a novel biased agonist of κ-opioid receptors with potent antipruritic activity. Proc Natl Acad Sci U S A (2016) 0.75
The BigLEN-GPR171 Peptide Receptor System within the Basolateral Amygdala Regulates Anxiety-Like Behavior and Contextual Fear Conditioning. Neuropsychopharmacology (2017) 0.75
A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci U S A (2004) 3.00
Building a new conceptual framework for receptor heteromers. Nat Chem Biol (2009) 2.41
D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism. Mol Pharmacol (2007) 2.28
mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol (2006) 1.93
Increased abundance of opioid receptor heteromers after chronic morphine administration. Sci Signal (2010) 1.90
Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers. FASEB J (2007) 1.89
G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. Pharmacol Rev (2014) 1.82
Hemopressin is an inverse agonist of CB1 cannabinoid receptors. Proc Natl Acad Sci U S A (2007) 1.70
The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol Sci (2007) 1.68
Systems approach to explore components and interactions in the presynapse. Proteomics (2009) 1.61
Morphine administration alters the profile of hippocampal postsynaptic density-associated proteins: a proteomics study focusing on endocytic proteins. Mol Cell Proteomics (2006) 1.43
Cell surface targeting of mu-delta opioid receptor heterodimers by RTP4. Proc Natl Acad Sci U S A (2008) 1.42
Regulation of CB1 cannabinoid receptor trafficking by the adaptor protein AP-3. FASEB J (2008) 1.40
Receptor heteromerization and drug discovery. Trends Pharmacol Sci (2010) 1.37
Conformation state-sensitive antibodies to G-protein-coupled receptors. J Biol Chem (2006) 1.37
Identification of a μ-δ opioid receptor heteromer-biased agonist with antinociceptive activity. Proc Natl Acad Sci U S A (2013) 1.34
Cannabinoid receptor-induced neurite outgrowth is mediated by Rap1 activation through G(alpha)o/i-triggered proteasomal degradation of Rap1GAPII. J Biol Chem (2005) 1.32
Exploring a role for heteromerization in GPCR signalling specificity. Biochem J (2011) 1.31
Multiple actions of spinophilin regulate mu opioid receptor function. Neuron (2008) 1.30
G protein-coupled receptor heteromerization: a role in allosteric modulation of ligand binding. Mol Pharmacol (2011) 1.27
Novel endogenous peptide agonists of cannabinoid receptors. FASEB J (2009) 1.25
The G alpha(o/i)-coupled cannabinoid receptor-mediated neurite outgrowth involves Rap regulation of Src and Stat3. J Biol Chem (2005) 1.25
AT1R-CB₁R heteromerization reveals a new mechanism for the pathogenic properties of angiotensin II. EMBO J (2011) 1.18
An emerging role for the delta opioid receptor in the regulation of mu opioid receptor function. ScientificWorldJournal (2007) 1.18
Oligomerization of opioid receptors. Methods (2002) 1.17
Serotonin receptor activation leads to neurite outgrowth and neuronal survival. Brain Res Mol Brain Res (2005) 1.14
Endoplasmic reticulum stress induces fibrogenic activity in hepatic stellate cells through autophagy. J Hepatol (2013) 1.12
Neuropeptide processing profile in mice lacking prohormone convertase-1. Biochemistry (2005) 1.09
GPCR-OKB: the G Protein Coupled Receptor Oligomer Knowledge Base. Bioinformatics (2010) 1.09
β2-Adrenergic receptor signaling in the cardiac myocyte is modulated by interactions with CXCR4. J Cardiovasc Pharmacol (2010) 1.08
Obesity and diabetes in transgenic mice expressing proSAAS. J Endocrinol (2004) 1.04
Grand opening of structure-guided design for novel opioids. Trends Pharmacol Sci (2012) 1.04
Cannabinoid receptor 2-mediated attenuation of CXCR4-tropic HIV infection in primary CD4+ T cells. PLoS One (2012) 1.03
Targeting opioid receptor heterodimers: strategies for screening and drug development. AAPS J (2006) 1.02
Interactions between delta opioid receptors and alpha-adrenoceptors. Clin Exp Pharmacol Physiol (2004) 1.02
Inquiry learning. Integrating content detail and critical reasoning by peer review. Science (2008) 1.02
Cannabinoid-opioid interactions during neuropathic pain and analgesia. Curr Opin Pharmacol (2009) 1.02
Allosteric interactions between δ and κ opioid receptors in peripheral sensory neurons. Mol Pharmacol (2011) 1.00
The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. Pharmacol Rev (2011) 0.99
Modulation of opiate-related signaling molecules in morphine-dependent conditioned behavior: conditioned place preference to morphine induces CREB phosphorylation. Neuropsychopharmacology (2009) 0.99
Hemoglobin-derived peptides as novel type of bioactive signaling molecules. AAPS J (2010) 0.97
The propeptide precursor proSAAS is involved in fetal neuropeptide processing and body weight regulation. J Neurochem (2010) 0.96
Neuroproteomics of the synapse and drug addiction. J Pharmacol Exp Ther (2006) 0.96
Insider access: pepducin symposium explores a new approach to GPCR modulation. Ann N Y Acad Sci (2009) 0.96
Opioid receptor heteromers in analgesia. Expert Rev Mol Med (2012) 0.94
Characterization of endothelin-converting enzyme-2. Implication for a role in the nonclassical processing of regulatory peptides. J Biol Chem (2003) 0.94
Peptidomics of Cpefat/fat mouse hypothalamus and striatum: effect of chronic morphine administration. J Mol Neurosci (2006) 0.94
Processing of proSAAS in neuroendocrine cell lines. Biochem J (2002) 0.93
An evaluation of a community pharmacy-based rural asthma management service. Aust J Rural Health (2008) 0.93
Teaching resources. Cell signaling systems: a course for graduate students. Sci STKE (2005) 0.93
Structural biology: How opioid drugs bind to receptors. Nature (2012) 0.92
Receptor heteromerization expands the repertoire of cannabinoid signaling in rodent neurons. PLoS One (2012) 0.91
Teaching resources. Using web-based discussion forums as a model of the peer-review process and a tool for assessment. Sci Signal (2008) 0.91
Homology modeling and site-directed mutagenesis to identify selective inhibitors of endothelin-converting enzyme-2. J Med Chem (2008) 0.90
Potentiation of μ-opioid receptor-mediated signaling by ketamine. J Neurochem (2011) 0.90
Antibodies against G-protein coupled receptors: novel uses in screening and drug development. Comb Chem High Throughput Screen (2008) 0.89
Chronic morphine alters the presynaptic protein profile: identification of novel molecular targets using proteomics and network analysis. PLoS One (2011) 0.88
GPR171 is a hypothalamic G protein-coupled receptor for BigLEN, a neuropeptide involved in feeding. Proc Natl Acad Sci U S A (2013) 0.87
Embryonic gene expression and pro-protein processing of proSAAS during rodent development. J Neurochem (2005) 0.86
Post-activation-mediated changes in opioid receptors detected by N-terminal antibodies. J Biol Chem (2008) 0.86
The use of receptor-specific antibodies to study G-protein-coupled receptors. Mt Sinai J Med (2006) 0.86
Functional relevance of μ-δ opioid receptor heteromerization: a role in novel signaling and implications for the treatment of addiction disorders: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend (2011) 0.85
Quantification of VGF- and pro-SAAS-derived peptides in endocrine tissues and the brain, and their regulation by diet and cold stress. Brain Res (2006) 0.84
Revolution in GPCR signalling: opioid receptor heteromers as novel therapeutic targets: IUPHAR review 10. Br J Pharmacol (2014) 0.84
Heteromers of μ-δ opioid receptors: new pharmacology and novel therapeutic possibilities. Br J Pharmacol (2014) 0.83
Possible involvement of prolonging spinal µ-opioid receptor desensitization in the development of antihyperalgesic tolerance to µ-opioids under a neuropathic pain-like state. Addict Biol (2011) 0.83
Dimerization with cannabinoid receptors allosterically modulates delta opioid receptor activity during neuropathic pain. PLoS One (2012) 0.83
Mechanisms of action of antidepressants: from neurotransmitter systems to signaling pathways. Cell Signal (2005) 0.82
Quantitative neuroproteomics of the synapse. Methods Mol Biol (2010) 0.82
Disease-specific heteromerization of G-protein-coupled receptors that target drugs of abuse. Prog Mol Biol Transl Sci (2013) 0.80
G-protein-coupled heteromers: regulation in disease. Methods Enzymol (2013) 0.80
Endothelin converting enzyme-2: a processing enzyme involved in the generation of novel neuropeptides. Protein Pept Lett (2004) 0.80
Orally active opioid μ/δ dual agonist MGM-16, a derivative of the indole alkaloid mitragynine, exhibits potent antiallodynic effect on neuropathic pain in mice. J Pharmacol Exp Ther (2013) 0.79
Mice deficient in endothelin-converting enzyme-2 exhibit abnormal responses to morphine and altered peptide levels in the spinal cord. J Neurochem (2011) 0.79
Use of proteomics for the identification of novel drug targets in brain diseases. J Neurochem (2007) 0.79
Escorts take the lead molecular chaperones as therapeutic targets. Prog Mol Biol Transl Sci (2010) 0.79
An integrated quantitative proteomics and systems biology approach to explore synaptic protein profile changes during morphine exposure. Neuropsychopharmacology (2013) 0.79
Role of antibodies in developing drugs that target G-protein-coupled receptor dimers. Mt Sinai J Med (2010) 0.79
A role for transmembrane domains V and VI in ligand binding and maturation of the angiotensin II AT1 receptor. Biol Chem (2006) 0.77
Identification of an endothelin-converting enzyme-2-specific fluorigenic substrate and development of an in vitro and ex vivo enzymatic assay. J Biol Chem (2010) 0.77
Possible involvement of β-endorphin in a loss of the coordinated balance of μ-opioid receptors trafficking processes by fentanyl. Synapse (2011) 0.77
Developmental changes in opioid peptides and their receptors in Cpe(fat)/Cpe(fat) mice lacking peptide processing enzyme carboxypeptidase E. J Pharmacol Exp Ther (2002) 0.75
Recombinant opioid receptors. Structure-function relationship. Methods Mol Med (2003) 0.75